Feline Anti-Nerve Growth Factor Study
Evaluation of the Pain Alleviating Effects of NV-02 in Cats Suffering from Degenerative Joint Disease-Associated Pain
We are seeking participants for a trial of a new biological compound, an antibody, that is being used to treat pain. It is a feline version of a compound being tested for arthritis pain control in humans. The treatment is NOT a non-steroidal anti-inflammatory (NSAID), and will administered once subcutaneously with an expected duration of effect of several weeks.
Description: The purpose of this study is to evaluate the efficacy of NV-02, an antibody to nerve growth factor, for the treatment of osteoarthritis pain in cats. This is a blinded, placebo controlled, pilot study. Thirty-six cats will be recruited into this study. Each cat will be evaluated over an 11-week period for changes in pain and mobility using various owner assessments, activity monitors, kinetic variables and veterinarian-assessed joint pain.
Eligibility: PERFORM SELF SCREEN FOR ELIGIBILITY HERE
Cats must satisfy the following criteria:
- Must have changes in activities due to DJD
- Must have radiographic changes on at least 2 joints confirmed by veterinarian exam
Cats with the following conditions will be excluded:
- Other conditions that may be causing immobility or pain (neurological disease, surgical alteration).
- Concurrent diseases and conditions including, but not limited to, cardiovascular disease, renal disease, liver disease, neoplasia, UTI, uncontrolled hypothyroidism, diabetes mellitus or infectious disease.
We need owners of cats to be able to commit to the following:
- Agree to evaluate their cat for a continuous 11-week period.
- Have a predictable and stable lifestyle (e.g. no impending house moves, new baby or pets).
- Bring cat in and come in for questionnaires on scheduled dates
Study incentives: The study will cover the cost of the examination, hospitalization, blood work and urinalysis, radiographs, and study drug. No other financial incentives are offered for participation.
Comparative Pain Research Laboratory at North Carolina State University, College of Veterinary Medicine (919) 513-6854 or email email@example.com
More Information about the NV-02 study:
The treatment is a new biological compound, an antibody to nerve growth factor. It is a feline version of a compound being tested for arthritis pain control in humans and dogs. The medication is NOT a non-steroidal anti-inflammatory (NSAID).
The treatment is given under your cat’s skin by a single injection, and the effect may last several weeks. This treatment is not yet approved for use in cats but has been evaluated for safety and efficacy in cats and offers a promising alternative to medications currently on the market for treatment of chronic pain in cats. Safety data showed no changes in kidney or liver enzyme values during treatment with single or repeat dosing. The treatment targets nerve growth factor, which has been shown to contribute to persistent pain and to be elevated in painful conditions such as arthritis. Treatment with anti-NGF has proven effective in decreasing pain in humans and dogs with arthritis, and in an inflammatory condition in cats.
- This is a double blind-controlled study which means your cat has a 33.3% chance of getting a placebo.
This is an 11-week study that involves having the cat come in 3 times and the owner for an additional 2 visits